Previous 10 | Next 10 |
2023-10-03 13:20:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Jeremy Siegel’s prediction that the Federal Reserve will not raise interest rates in November, despite the pressure from higher bond yields on the equities market, holds si...
YAVNE, Israel, Sept. 26, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today announced that the U.S. Department of Defense (DoD), through the Medical Technology Enterprise C...
2023-09-21 14:15:44 ET More on MediWound Seeking Alpha’s Quant Rating on MediWound Financial information for MediWound MediWound Ltd. (MDWD) Q2 2023 Earnings Call Transcript MediWound GAAP EPS of $0.10 beats by $0.47, revenue of $4.77M beats by $0.59M ...
YAVNE, Israel, Sept. 21, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today announced the U.S. commercial availability of NexoBrid ® (anacaulase-bcdb) for the remo...
YAVNE, Israel, Sept. 11, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (“MediWound”), a fully integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today announced its successful participation at the recently con...
YAVNE, Israel, Sept. 05, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today announced its participation in the upcoming H.C. Wainwright 25 th Annual Global Investment C...
2023-08-16 13:49:09 ET MediWound Ltd. (MDWD) Q2 2023 Earnings Call Transcript August 16, 2023 08:30 AM ET Company Participants Monique Kosse - LifeSci Advisors, IR Ofer Gonen - Chief Executive Officer Barry Wolfenson - Executive Vice President of Strategy & C...
2023-08-15 16:34:38 ET MediWound press release ( NASDAQ: MDWD ): Q2 GAAP EPS of $0.10 beats by $0.47 . Revenue of $4.77M (+2.1% Y/Y) beats by $0.59M . As of June 30, 2023, the Company's cash and short-term deposits were $51.3 million, compared to $34.1 million ...
EscharEx ® Phase III study protocol : FDA/EM A-aligned ; p atient enrollment commencing early 2024 ; two key research collaborations with wound industry leaders NexoBrid ® U.S. commercial launch timing ...
YAVNE, Israel, Aug. 15, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today announced a research collaboration agreement with Mölnlycke for its upcoming Phase III study...
News, Short Squeeze, Breakout and More Instantly...
Funds to be used for clinical development of EscharEx ® to treat diabetic foot ulcers (DFUs) Award advances MediWound’s DFU program and its future revenues four years ahead of original schedule YAVNE, Israel, July 16, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd....
Mölnlycke® Health Care announces US $15m investment in next-generation enzymatic therapeutics company MediWound Ltd PR Newswire GOTHENBURG, Sweden , July 15, 2024 /PRNewswire/ -- Mölnlycke Health Care, a world-leading MedTech company specialising i...
YAVNE, Israel, July 15, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the world leader in next-generation enzymatic therapeutics for tissue repair, today announced it has entered into a definitive share purchase agreement with several new and existing investors, including Mölnlycke...